Trials / Not Yet Recruiting
Not Yet RecruitingNCT06787950
Clinical Study of ASN-3186 in Patients with Advanced Solid Tumors
A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Anti-tumor Activity of ASN-3186 in Patients with Advanced Solid Tumors.
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Jiangsu Yahong Meditech Co., Ltd aka Asieris · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I/IIa, open-label, multi-center, dose-escalation, and expansion study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of ASN-3186 when given orally in subjects with advanced solid tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASN-3186 | ASN-3186 will be administered orally. |
| DRUG | ASN-3186 | ASN-3186 will be administered orally. |
| DRUG | ASN-3186 | ASN-3186 will be administered orally. |
Timeline
- Start date
- 2025-02-20
- Primary completion
- 2029-03-20
- Completion
- 2029-09-20
- First posted
- 2025-01-22
- Last updated
- 2025-01-22
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06787950. Inclusion in this directory is not an endorsement.